Cipla Doubles Remdesivir Production In India For "Unprecedented" Demand The COVID-19 pandemic brought the world to its knees with its sheer virulence and adaptive ability. It forced the scientific community to work at an unprecedented pace to develop therapeutic regimens and vaccines to combat it. As researchers turned to existing drugs with the hopes of tackling the SARS-CoV-2 virus, one drug emerged as a viable candidate— Remdesivir. Now, the drug manufactured by the US-based pharmaceutical company, Gilead Sciences, is being turned to as a savior. Reports emerging from across India have stated that there is an acute shortage of Remdesivir, and sky-rocketing prices; highlighting not just the demand for the drug, but also the faith in it as the second wave sweeps the country. Let us take a look at Remdesivir's journey in the fight against COVID-19